In a significant development, Mecwins’ General Manager, Oscar Ahumada, and Senior R&D Engineer, Antonio Salvador, have set off on a two-day exploratory journey to the acclaimed FAPON Biotech Inc. The journey charted a course to the recognized heart of biotech innovation, the Shenzhen Bay Area.
FAPON Biotech, a name that resonates with dedication and innovation, has marked its supremacy in the global diagnostic landscape with its top-notch IVD reagent raw materials including antigens, antibodies, and enzymes, as well as ground-breaking chemiluminescence platforms. Now, the company is expanding its vista to embrace the ultrasensitive single molecule counting technologies and has shown an interest in Mecwins’ state-of-the-art optoplasmonic AVAC technology. This developing relationship holds the promise of blending the strengths of both companies, setting the stage for technological advancements in the field.
The exploratory journey initiated with a visit to FAPON’s sprawling production facilities in Dongguan, offering a sneak peek into the grandeur of the operation. Day two unfolded with a visit to FAPON’s impressive headquarters in Shenzhen, where the duo from Mecwins was warmly greeted by FAPON’s esteemed CEO, Cui Peng, and President, He Zhiqiang.
By presenting the AVAC technology to key members of FAPON, Mecwins has taken a leap toward forging a synergistic relationship that promises to mutually benefit both organizations. With a shared vision and a promise of a bright future, we eagerly look forward to seeing the outcomes of this interaction. As the world of biotech braces for potential new developments, we commit to keeping you updated on the exciting progress this collaboration promises to bring.
